Pyxis Oncology 2025 net loss widens on higher R&D spend

Overview

• US biopharmaceutical developer's 2025 revenue fell yr/yr, net loss widened

• Company completed target enrollment in MICVO Phase 1 monotherapy study for head and neck cancer

• Pyxis Oncology expects cash runway into fourth quarter of 2026

Outlook

• Pyxis Oncology expects cash runway into the fourth quarter of 2026

Result Drivers

• REVENUE SOURCES - 2025 revenue driven by regulatory milestone for suvemcitug approval in China and sale of royalty rights for Enzeshu

• R&D SPENDING - Higher research and development expenses due to increased contract manufacturing and clinical trial costs for MICVO

• COST REDUCTION - Lower general and administrative expenses mainly from reduced employee-related costs, insurance, and professional fees

Company press release: ID:nGNX6k2FkC

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.00, about 376.2% above its March 20 closing price of $1.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.